Chemkart India Ltd (CHEMKART) is currently trading at 268.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Chemkart India Limited is a B2B processor and trader of nutritional, sports-nutrition and health-supplement ingredients, supplying more than 150 ingredients to manufacturers across India. Its portfolio includes amino acids, proteins, herbal extracts, nucleotides, vitamins and specialty supplement ingredients, supported by blending, grinding, packing and warehousing infrastructure in Bhiwandi, Maharashtra. The company delivered a sharp acceleration in H1 FY27, with consolidated revenue rising 99.4% year-on-year to INR 205.9 crore, EBITDA increasing 107.5% to INR 29.4 crore and PAT growing 122.2% to INR 22.6 crore. Revenue generated in six months nearly matched FY26 revenue, although working-capital absorption materially weakened operating cash flow. Chemkart India Limited is attempting a significant business-model transition from distribution toward higher-value manufacturing and CDMO services. Its greenfield JNPA SEZ facility is being designed around formulation, packaging, export logistics and advanced delivery technologies, potentially improving differentiation and margins if construction, qualification and customer onboarding proceed as planned. The company remains overwhelmingly domestic, with exports contributing only 0.39% of reported revenue, despite identifying global expansion as a central strategic objective. This creates substantial runway but also means the stated international ambition is presently prospective rather than an established revenue engine. Amino acids represented 50.0% of H1 FY27 revenue, while sports nutrition contributed 28.8% and protein increased to 8.4% from 2.3% in FY26. The mix demonstrates strong exposure to performance nutrition and amino-acid demand, while also indicating concentration in a limited number of product categories.

Over the past 52 weeks, Chemkart India Ltd has traded between a low of ₹87.00 and a high of ₹268.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Chemkart India Ltd has a market capitalization of approximately 324.98. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Chemkart India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 10.13 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 324.98 Cr, Chemkart India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Chemkart India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Chemkart India Ltd is 10.13. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Chemkart reported that Amino Acids accounted for 50.0% of H1 FY27 segment-wise revenue. The category generated Rs 102.86 crore out of total product-category revenue of Rs 205.87 crore.

Chemkart recorded a Rs 45.56 crore use of working capital in its September 2026 cash-flow statement. That amount exceeded Rs 30.29 crore of operating profit before working-capital changes, while direct taxes paid added Rs 3.44 crore to cash use. Net operating cash flow was therefore negative Rs 18.71 crore.

Chemkart reported consolidated revenue from operations of Rs 205.873 crore in H1 FY27. This was 99.4% higher than Rs 103.226 crore in H1 FY26 and 84.5% above Rs 111.604 crore in H2 FY26.

Chemkart is building a greenfield nutraceutical CDMO facility through Easy Raw Materials Private Limited at JNPA SEZ in Raigad, Maharashtra. The planned operation covers formulation, packaging and global dispatch, with tablets, capsules, jars and sachets listed as dosage formats.